Spero Therapeutics Stock Performance

SPRO Stock  USD 2.45  0.01  0.41%   
Spero Therapeutics has a performance score of 3 on a scale of 0 to 100. The entity has a beta of 1.5, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Spero Therapeutics will likely underperform. Spero Therapeutics right now has a risk of 2.52%. Please validate Spero Therapeutics semi variance, and the relationship between the sortino ratio and rate of daily change , to decide if Spero Therapeutics will be following its existing price patterns.

Risk-Adjusted Performance

Soft

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Spero Therapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Spero Therapeutics may actually be approaching a critical reversion point that can send shares even higher in February 2026. ...more

Actual Historical Performance (%)

One Day Return
0.41
Five Day Return
4.7
Year To Date Return
4.26
Ten Year Return
(78.70)
All Time Return
(78.70)
1
Spero Therapeutics Inc. stock trendline breakdown - Quarterly Earnings Report Consistent Profit Trading Strategies - newser.com
11/05/2025
2
Why Spero Therapeutics Inc. stock is favored by hedge funds - Bond Market Stepwise EntryExit Trade Alerts - newser.com
11/18/2025
3
Aug Mood Will Spero Therapeutics Inc. stock reach all time highs in 2025 - July 2025 Patterns AI Forecasted Entry and Exit Points - B NI V
11/26/2025
4
Acquisition by Tregoning Kathleen of 15000 shares of Spero Therapeutics subject to Rule 16b-3
11/28/2025
5
Spero Therapeutics Stock Rating Lowered by Wall Street Zen - MarketBeat
12/05/2025
6
Is Spero Therapeutics In A Good Position To Deliver On Growth Plans
12/15/2025
7
Spero Therapeutics, Inc. Sees Large Growth in Short Interest - MarketBeat
12/31/2025
8
Disposition of 9504 shares by Shukla Sath of Spero Therapeutics at 1.8279 subject to Rule 16b-3
01/02/2026
9
Evercore Maintains Spero Therapeutics With Hold Rating, Maintains Target Price 4 -
01/06/2026
10
Aug PostEarnings What are Spero Therapeutics Incs recent SEC filings showing - IPO Watch Consistent Income Trade Ideas - baoquankhu1.vn
01/13/2026
11
SEC Settlement Resolves Past Disclosure Issues for Spero Therapeutics - AD HOC NEWS
01/20/2026

Spero Therapeutics Relative Risk vs. Return Landscape

If you would invest  233.00  in Spero Therapeutics on October 29, 2025 and sell it today you would earn a total of  12.00  from holding Spero Therapeutics or generate 5.15% return on investment over 90 days. Spero Therapeutics is currently generating 0.1138% in daily expected returns and assumes 2.5161% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Spero, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Spero Therapeutics is expected to generate 3.37 times more return on investment than the market. However, the company is 3.37 times more volatile than its market benchmark. It trades about 0.05 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.09 per unit of risk.

Spero Therapeutics Target Price Odds to finish over Current Price

The tendency of Spero Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 2.45 90 days 2.45 
about 23.95
Based on a normal probability distribution, the odds of Spero Therapeutics to move above the current price in 90 days from now is about 23.95 (This Spero Therapeutics probability density function shows the probability of Spero Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.5 . This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Spero Therapeutics will likely underperform. Additionally Spero Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Spero Therapeutics Price Density   
       Price  

Predictive Modules for Spero Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Spero Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.122.454.97
Details
Intrinsic
Valuation
LowRealHigh
0.503.025.54
Details
Naive
Forecast
LowNextHigh
0.052.394.90
Details
3 Analysts
Consensus
LowTargetHigh
3.644.004.44
Details

Spero Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Spero Therapeutics is not an exception. The market had few large corrections towards the Spero Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Spero Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Spero Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.03
β
Beta against Dow Jones1.50
σ
Overall volatility
0.1
Ir
Information ratio 0

Spero Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Spero Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Spero Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
The company reported the previous year's revenue of 47.98 M. Net Loss for the year was (68.57 M) with loss before overhead, payroll, taxes, and interest of (21.16 M).
Spero Therapeutics currently holds about 45.4 M in cash with (23.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29.
Spero Therapeutics has a frail financial position based on the latest SEC disclosures
Roughly 23.0% of the company outstanding shares are owned by corporate insiders
Latest headline from news.google.com: SEC Settlement Resolves Past Disclosure Issues for Spero Therapeutics - AD HOC NEWS

Spero Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Spero Stock often depends not only on the future outlook of the current and potential Spero Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Spero Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding54 M
Cash And Short Term Investments52.9 M

Spero Therapeutics Fundamentals Growth

Spero Stock prices reflect investors' perceptions of the future prospects and financial health of Spero Therapeutics, and Spero Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Spero Stock performance.

About Spero Therapeutics Performance

By examining Spero Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Spero Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Spero Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand(108.71)(114.15)
Return On Tangible Assets(0.56)(0.59)
Return On Capital Employed(1.07)(1.13)
Return On Assets(0.56)(0.59)
Return On Equity(1.34)(1.40)

Things to note about Spero Therapeutics performance evaluation

Checking the ongoing alerts about Spero Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Spero Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
The company reported the previous year's revenue of 47.98 M. Net Loss for the year was (68.57 M) with loss before overhead, payroll, taxes, and interest of (21.16 M).
Spero Therapeutics currently holds about 45.4 M in cash with (23.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29.
Spero Therapeutics has a frail financial position based on the latest SEC disclosures
Roughly 23.0% of the company outstanding shares are owned by corporate insiders
Latest headline from news.google.com: SEC Settlement Resolves Past Disclosure Issues for Spero Therapeutics - AD HOC NEWS
Evaluating Spero Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Spero Therapeutics' stock performance include:
  • Analyzing Spero Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Spero Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Spero Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Spero Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Spero Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Spero Therapeutics' stock. These opinions can provide insight into Spero Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Spero Therapeutics' stock performance is not an exact science, and many factors can impact Spero Therapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
When determining whether Spero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Spero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spero Therapeutics Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.753
Earnings Share
(0.79)
Revenue Per Share
0.73
Quarterly Revenue Growth
(0.60)
Return On Assets
(0.30)
The market value of Spero Therapeutics is measured differently than its book value, which is the value of Spero that is recorded on the company's balance sheet. Investors also form their own opinion of Spero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spero Therapeutics' market value can be influenced by many factors that don't directly affect Spero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.